Earli

These programmable synthetic promoter-reporter sequences "flip on" like light switches only in dysregulated cancer cells and turn them into "factories.". Earli has raised $82m in three rounds from investors including Andreessen Horowitz, Khosla Ventures, Emerson Collective, Stanford, Perceptive Advisors, Casdin Capital, Marc Benioff, Sands Capital, Breyer Capital, Tailwinds (American-Korean) etc.. Its Scientific Advisory Board includes Jim Allison (Nobel Laureate, Immuno Oncology), Bob Langer (MIT, co-founder Moderna), Phil Greenberg (Hutch, co-founder Juno), Pam Sharma (MD Anderson), Charlie Rudin (Sloan Kettering), Alan Ashworth (UCSF Cancer Center).. Demonstrated track record (as evidenced in your deal sheet) that covers the range from scouting, to designing, to negotiating, to implementing biotech deals, including with large pharma with an emphasis on sell-side deals. Familiarity with cancer therapeutics, immuno-oncology, molecular biology, and related technologies is ideal but not required

sr director business development

<p>About Earli
Earli exists to make cancer a benign experience. Earli does that by turning cancers against themselves: genetically forcing them to reveal themselves early, and then kill themselves - precisely and clearly distinguishable from benign lesions at early stages. Based on original technology from Stanford's renowned Gambhir lab, Earli designs genetic constructs that are injected intravenously that turn cancer cells against themselves. These programmable synthetic promoter-reporter sequences "flip on" like light switches only in dysregulated cancer cells and turn them into "factories." The cancer is forced to produce either an epitope "docking station" for imaging agents, or a cytokine for immune system activation against the tumor. Thus, Earli's platform enables immediate diagnosis and treatment of early cancers, rather than long-term observation that can lead to deadly metastatic recurrence.
Earli's synthetic target expression platform has evolved over five years of deep bioengineering. The system can now detect broad ranges of patient mutations, distinguish between malignant and benign lesions, and offer independence from often elusive natural biomarkers.
Earli has raised $82m in three rounds from investors including Andreessen Horowitz, Khosla Ventures, Emerson Collective, Stanford, Perceptive Advisors, Casdin Capital, Marc Benioff, Sands Capital, Breyer Capital, Tailwinds (American-Korean) etc.
Its Scientific Advisory Board includes Jim Allison (Nobel Laureate, Immuno Oncology), Bob Langer (MIT, co-founder Moderna), Phil Greenberg (Hutch, co-founder Juno), Pam Sharma (MD Anderson), Charlie Rudin (Sloan Kettering), Alan Ashworth (UCSF Cancer Center).
Who You Are
* You share our same sense of dedication, scientific passion and entrepreneurial spirit
* You work well in a fast-paced and extremely focused startup environment
* You are not only smart, but clever and constantly think outside the box
* You are able to make logical decisions in an instant when there is little time to evaluate
* You are a natural communicator and relationship builder
* You stay calm under high pressure and stress
* You have the ability to multi-task in a serious way, with an extreme attention to detail
* You become a representative of the core DNA of the company through who you are
The Position
Earli Inc. is seeking a high-caliber Senior Director of Business Development to lead our revenue-driving strategic pharma and biotech collaborations, partnerships and outlicensing deals.
Your Primary Responsibilities
As Earli's Senior Director of Business Development you will be a strategic dealmaker - an individual deeply connected to major pharmaceutical companies, with a proven track record of making deals for collaborations or outlicensing. This role is about developing and driving strategic partnerships and revenue with large pharma companies and successful biotech players in the industry.
You will:
* Identify and execute non-dilutive funding arrangements for the company.
* Source, set up, negotiate, and implement R&D collaborations with major pharmaceutical companies.
* Leverage existing and build new relationships with key stakeholders in major pharmaceutical companies.
* Source, set up, negotiate, and implement outlicensing agreements for biological and delivery components with biotech companies.
* Lead deal-making and negotiation efforts.
* Drive the BD process to meet and exceed revenue targets through strategic partnerships.
* Analyze competitive landscape for Earli's products and contribute key insights to development strategy.
* Evangelize Earli's technology platform and create awareness of its capabilities and how it's different to other platforms.
* Report industry trends, competitor activities, and regulatory changes related to pharmaceutical partnerships to company leadership.
* Utilize market intelligence to inform deal-making strategies and revenue generation.
* Lead in-licensing deal process for biological or delivery components.
Your Required Experience, Knowledge and Skills
* Demonstrated track record (as evidenced in your deal sheet) that covers the range from scouting, to designing, to negotiating, to implementing biotech deals, including with large pharma with an emphasis on sell-side deals
* Bachelor's Degree in business, Life Sciences, or a related field. MBA or advanced degree preferred
* Minimum of 8 years of relevant experience in business development with a focus on the healthcare or life sciences industry
* Proven track record of successfully leveraging top-level pharma relationships and driving business growth
* Strong negotiation and communication skills
* Ability to think strategically, analyze data, and make informed decisions
* Excellent leadership and team management skills
* Familiarity with cancer therapeutics, immuno-oncology, molecular biology, and related technologies is ideal but not required
* Excellent verbal communication and interpersonal skills
* Ability to lead projects independently, multi-task effectively, and integrate fully into a high achieving team environment
If interested in applying, please attach a CV or have a well-developed LinkedIn profile for us to be able to assess your background.
We look forward to hearing from you! <br><br>#J-18808-Ljbffr</p>

START NEW SEARCH